3-(4-chlorophenyl)imidazo[2,1-b]thiazol-6(5H)-one

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(4-chlorophenyl)imidazo[2,1-b]thiazol-6(5H)-one
• 英文别名: 3-(4-chlorophenyl)-5H-imidazo[2,1-b][1,3]thiazol-6-one
• 化学式: C₁₁H₇ClN₂OS
• 分子量: 250.708
• InChiKey: OZSGMUVOGHBQRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  58
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)imidazo[2,1-b]thiazol-6(5H)-one 在 一水合肼 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 1-(3-(4-chlorophenyl)imidazo[2,1-b]thiazol-6-yl)-3-methyl-1H-pyrazol-5(4H)-one
  参考文献：
  名称：

  新型吡唑并咪唑并[2,1- b ]噻唑衍生物的合成，体外抗癌评价和计算机模拟研究

  摘要：

  一系列咪唑并[2,1-的b ]噻唑轴承吡唑结构部分4 - 6（一- ç）通过6- hydrazinylimidazo [2,1的反应合成b ]噻唑3A - Ç不同β二羰基化合物。在美国国家癌症研究所（NCI）筛选了11种化合物的单剂量（10μM）的抗癌活性。的体外抗癌评估表明，化合物2A和4 - 6（一）朝向显示出增加的效力CNS SNB-75和肾UO-31癌细胞系。COMPARE分析显示与雷帕霉素（mTOR抑制剂）有很强的相关性。化合物2a和4 – 6（a）的毒性，药物相似性和药物评分曲线的评估结果令人鼓舞。一些目标化合物与潜在的抗癌目标显示出良好的对接分数，这是基于已建立的衍生物的药效基团图谱选择的。

  DOI：

  10.1016/j.ejmech.2013.12.010
• 作为产物：
  描述：

  2'-溴-4-氯苯乙酮 在 sodium acetate 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 生成 3-(4-chlorophenyl)imidazo[2,1-b]thiazol-6(5H)-one
  参考文献：
  名称：

  Novel acetamidothiazole derivatives: Synthesis and in vitro anticancer evaluation

  摘要：

  A novel series of acetamide derivatives possessing both 2-imino-4-arylthiazoles and morpholine or different piperazines were synthesized and characterized by IR, 1H NMR, 13C NMR, elemental and mass spectral analyses. Twelve compounds were granted NSC codes at National Cancer Institute (NCI), USA for anticancer activity at a single high dose (10 s M) in full NCI 60 cell panel. Among the compounds tested, compounds 5a and 6b were found to be the most active candidates of the synthesized series. Assessment of toxicities, druglikeness, and drug score profiles of compounds 5a and 6b are promising. Some of the synthesized compounds showed a good docking score with potential anticancer targets, chosen based on pharmacophore mapping of the established derivatives. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.021

文献信息

• Swathi; Kumar, T. Durai Ananda; Haribabu, Indian Journal of Heterocyclic Chemistry, 2012, vol. 22, # 1, p. 41 - 46
  作者：Swathi、Kumar, T. Durai Ananda、Haribabu、Subrahmanyam

  DOI：——

  日期：——
• Swathi; Durai Ananda Kumar; Haribabu, Indian Journal of Heterocyclic Chemistry, 2012, vol. 21, # 3, p. 263 - 268
  作者：Swathi、Durai Ananda Kumar、Haribabu、Subrahmanyam

  DOI：——

  日期：——
• Synthesis, in vitro anticancer evaluation and in silico studies of novel imidazo[2,1-b]thiazole derivatives bearing pyrazole moieties
  作者：Ahmed R. Ali、Eman R. El-Bendary、Mariam A. Ghaly、Ihsan A. Shehata

  DOI：10.1016/j.ejmech.2013.12.010

  日期：2014.3

  of 6-hydrazinylimidazo[2,1-b]thiazoles 3a–c with different β-dicarbonyl compounds. Eleven compounds were screened at the National Cancer Institute (NCI), USA for anticancer activity at a single dose (10 μM). The in vitro anticancer evaluation revealed that compounds 2a and 4–6(a) exhibited increased potency towards CNS SNB-75 and Renal UO-31 cancer cell lines. COMPARE analyses showed strong to considerable

  一系列咪唑并[2,1-的b ]噻唑轴承吡唑结构部分4 - 6（一- ç）通过6- hydrazinylimidazo [2,1的反应合成b ]噻唑3A - Ç不同β二羰基化合物。在美国国家癌症研究所（NCI）筛选了11种化合物的单剂量（10μM）的抗癌活性。的体外抗癌评估表明，化合物2A和4 - 6（一）朝向显示出增加的效力CNS SNB-75和肾UO-31癌细胞系。COMPARE分析显示与雷帕霉素（mTOR抑制剂）有很强的相关性。化合物2a和4 – 6（a）的毒性，药物相似性和药物评分曲线的评估结果令人鼓舞。一些目标化合物与潜在的抗癌目标显示出良好的对接分数，这是基于已建立的衍生物的药效基团图谱选择的。
• Novel acetamidothiazole derivatives: Synthesis and in vitro anticancer evaluation
  作者：Ahmed R. Ali、Eman R. El-Bendary、Mariam A. Ghaly、Ihsan A. Shehata

  DOI：10.1016/j.ejmech.2013.08.021

  日期：2013.11

  A novel series of acetamide derivatives possessing both 2-imino-4-arylthiazoles and morpholine or different piperazines were synthesized and characterized by IR, 1H NMR, 13C NMR, elemental and mass spectral analyses. Twelve compounds were granted NSC codes at National Cancer Institute (NCI), USA for anticancer activity at a single high dose (10 s M) in full NCI 60 cell panel. Among the compounds tested, compounds 5a and 6b were found to be the most active candidates of the synthesized series. Assessment of toxicities, druglikeness, and drug score profiles of compounds 5a and 6b are promising. Some of the synthesized compounds showed a good docking score with potential anticancer targets, chosen based on pharmacophore mapping of the established derivatives. (C) 2013 Elsevier Masson SAS. All rights reserved.